What is the half-life of Myostatin Propeptide?

Myostatin Propeptide has a half-life of Estimated 2-4 hours (short, no Fc fusion), which is why it's typically administered Once daily (research dosing, not clinically established) for optimal therapeutic effect.

How do I reconstitute Myostatin Propeptide?

Add bacteriostatic water to the peptide vial slowly down the side. Typical reconstitution uses 2-3ml of water for a 5mg vial. Gently swirl, do not shake.

Muscle Growth

Preclinical

Myostatin Propeptide

Also known as: GDF-8 Propeptide, MSTN Propeptide, Myostatin Inhibitor Propeptide

Overview

Key Facts

Primary Goal: The N-terminal propeptide of myostatin that naturally maintains myostatin in an inactive latent complex

The N-terminal propeptide of myostatin that naturally maintains myostatin in an inactive latent complex. When administered exogenously, it binds to and inhibits mature myostatin with high specificity, offering a more targeted approach to myostatin inhibition compared to broader TGF-beta pathway blockers like ACE-031 or Follistatin. Half-Life Estimated 2-4 hours (short, no Fc fusion) Typical Dose 50–200 mcg Frequency Once daily (research dosing, not clinically established) Cycle Length 4-8 weeks (research protocols only)

Dosing Information

Half-Life

Estimated 2-4 hours (short, no Fc fusion)

Typical Dose

50–200 mcg

Frequency

Once daily (research dosing, not clinically established)

Cycle Length

4-8 weeks (research protocols only)

Administration Routes:

subcutaneousintramuscular

Storage & Reconstitution

Unreconstituted (Powder)

Temperature2–8°C (36–46°F) or -20°C (-4°F) for long-term

DurationUp to 3 months

Reconstituted (Mixed)

Temperature2–8°C (36–46°F)

Duration2-4 weeks

Research Summary

Preclinical

The myostatin propeptide has been extensively studied in animal models. Transgenic mice overexpressing the propeptide exhibit 20-40% increases in muscle mass. Engineered variants with enhanced affinity (e.g., D76A mutant) show even greater efficacy. While no direct clinical trials of the injectable peptide exist, gene therapy approaches delivering the propeptide are in preclinical development for muscular dystrophies.